October 19, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today...

recent articles

MMI officially launches their latest imaging solution at the Digital Pathology congress in London, UK. The MMI CellScan is a new stand-alone system for Whole Slide Imaging. Researchers are now able to scan full resolution digital slides in...

Proving once again humor is the best medicine. Pathology parody on "A Million Dreams". Unfortunately, this is a million slides. Credits at the...

My father used to say "You can get anything you need at a hardware store." I used to love going with him to the local Ace Hardware and getting the special screws or bolts and tools for a particular project. The smell, the merchandise packed...

REGISTER NOW Imagine an APP for nuclei segmentation that is reliable and can be used by anyone in your lab. Recent advances in deep learning and artificial intelligence have enabled Visiopharm to develop novel tools for nuclei...

The Danish-based leader in augmented pathology solutions Visiopharm has secured a grant worth £250,000 from UK Research and Innovation to test its innovative solutions in partnership with the NHS. The grant, offered by the UK Government’s...

OR

platinum partners

gold partners

Silver Partners

Media Partners